Marburg i mutant of factor vii-activating protease (fsap) as risk factor for arterial thrombosis
CA 2422583 C · Owner: Csl Behring Gmbh · Inventors: Wiedermann, Christian Josef; Stoehr, Hans-Arnold; Kiechl, Stefan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel arterial thrombosis risk factor which consists in particular of one of the identified mutants of coagulation factor VII-activating protease (=FSAP) is described. In addition diagnostic determination methods for detecting these mutants which are identified as risk factors are described.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 18, 2003 and granted May 13, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 18, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 18, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.